COMPARE · Reviewed August 7, 2026
ANIP vs HALO
Verdict: Side-by-side breakdown using the Bull Rankings model. ANIP scored 83.9, HALO scored 82.7 — ANIP leads.
Compare another set
Different reporting periods. HALO's fundamentals are as of June 2026, but ANIP's are as of March 2026 — a 3-month gap. Growth, margin and valuation figures below therefore describe different windows and aren't strictly like-for-like.
ANIP
ANI Pharmaceuticals, Inc.
83.9
$82.63 · $1.9B
fundamentals as of
Score gap
1.2
ANIP leads
HALO
Halozyme Therapeutics, Inc.
82.7
$85.76 · $10.2B
fundamentals as of
The model, pillar by pillar (0–100 each)
ANIP
stronger →← stronger
HALO
64
Qualityreturns · margins · balance sheet
85
100
Growthrevenue & earnings expansion
100
92
Valuevaluation vs sector peers
67
ANIP and HALO split the three pillars evenly.
Fundamentals, head-to-head
ANIP
HALO
$191mC
FCF
$806mC+
+37.0%A
Rev
+41.2%A
1.12C
D/E
9.91D
21.1xB+
P/E
30.1xB
0.48A
PEG
0.80A-
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
ANIP
HALO
48% below
Price vs fair valuelower is cheaper
51% below
~-7%/yr
Growth the price implies10-yr FCF · lower = less priced in
~-4%/yr
+66%
1-yr DCF upside
+59%
+92%
5-yr DCF upside
+105%
+135%
10-yr DCF upside
+200%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ANIP
No notable signals flagged.
HALO
Why this score
- Buying back stock
- Durable high returns
The companies
ANIPANI Pharmaceuticals, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $1.9b. 17% off the 52-week high of $99.50. Revenue growing +37% — in hypergrowth territory. PEG 0.48 — paying under fair value for the growth rate. 8 sell-side analysts rate this a Buy with a mean 1-yr target of $110.00 (implying +33% upside).
Moat
ROE 16% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
HALOHalozyme Therapeutics, Inc.
Why now
Biotechnology · market cap $10.2b. Trading near 52-week high of $86.00 — momentum setup, limited technical margin of safety. Revenue growing +41% — in hypergrowth territory. PEG 0.80 — paying under fair value for the growth rate. 9 sell-side analysts rate this a Buy with a mean 1-yr target of $86.89 (implying +1% upside).
Moat
Net margin 25% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. FCF converts 195% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
D/E 9.91 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Trading within 0% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trailing P/E 30x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.